Keywords
How to Cite
Abstract
Objective: To evaluate the effectiveness of somatostatin, lanreotide, octreotide, and pasireotide analogs in the control of GH, IGF-1, and tumor size in a cohort of patients with acromegaly. Materials and methods: an observational, retrospective, analytical, single-center study of patients with acromegaly in a highly complex center in the city of Cali - Colombia. To evaluate the effectiveness, bivariate analysis was used, contingency tables, chi-square, one-way ANOVA were made in a general linear model of one and two-way repeated measures, ? ? 0.05. Results: 29 patients were included, 52% were men. The mean age was 54.8 years (range: 28-79 years). The average levels of GH and IGF-1 were 13.7ng / dl and 776 ng / ml, respectively. The average tumor size was 17.2 mm. Decreased levels of GH and IGF-1 were found in all patients, regardless of the medication received. A decrease in tumor size was observed in the 12-month follow-up of 41.6%. Regarding the adequate control criteria, 27.6% of patients reached it after one year of treatment, of which 62.5% were women and 37.5% were receiving pasireotide, the rest received lanreotide. Conclusions: Somatostatin analogs were effective in reducing the levels of GH, IGF-1, and the size of the pituitary adenoma.
References
Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CMG, Pinedo AC, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448–57.
Caamaño-Villafañe P, Gill-Barretoa S, Ramos-Villegas Y, Corrales-Santander H, Pacheco-Hernández A, Picón Y, et al. Acromegalia y adenomas hipofisiarios: una revisión de la literatura. Cienc e Innovación en Salud [Internet]. 2019;e76:1–9. Available from: http://revistas.unisimon.edu.co/index.php/innovacionsalud/article/view/3618
Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. Eur Endocrinol. 2018;14(2):57.
Pérez AV, Cañón LA, Vanegas EP, Rojas W, Lammoglia J, Pautt T. Efectividad y seguridad de lanreótide y octreótido en personas con diagnóstico de gigantismo o de acromegalia. Rep No 106 Bogotá, DC Inst Evaluación Tecnológica en Salud-IETS y Minist Salud y Protección Soc. 2014;1–59.
Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.
Coopmans EC, Postma MR, Wolters TLC, van Meyel SWF, Netea-Maier R, van Beek AP, et al. Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study. J Clin Endocrinol Metab. 2021;106(6):1783–92.
Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol [Internet]. 2018;14(9):552–61. Available from: http://dx.doi.org/10.1038/s41574-018-0058-5
Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab [Internet]. 2014;99(11):3933–51. Available from: file:///Users/nataliabuitrago/Documents/residencia medicina interna/Estudios/Acromegalia Novartis/Artículos/Katznelson L, Laws ER, Jr., Melmed S, et al. Acromegaly- an endocrine society clinical practice guideline. The Journal of clinical endocrinology an
Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ. Control of growth hormone and IGF1 in patients with acromegaly in the UK: Responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013;79(5):689–99.
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–68.
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282–90.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9.
Ben-Shlomo A. Pharmacotherapy for Acromegaly. Future Role for Pasireotide? Endocrinol Metab Clin North Am [Internet]. 2015;44(1):35–41. Available from: http://dx.doi.org/10.1016/j.ecl.2014.10.004
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.
Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary [Internet]. 2021;24(1):1–13. Available from: https://doi.org/10.1007/s11102-020-01091-7
Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Bima C, Vita MG, et al. Acromegaly can be cured by first-line pasireotide treatment? Endocrine [Internet]. 2019;64(1):196–9. Available from: http://dx.doi.org/10.1007/s12020-019-01874-4
Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al. Clinical case seminar: Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92(5):1592–9.
Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002;56(1):65–71.
Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: A prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56.
Ghajar AA, Jones P, Guarda FJ, Faje A, Nicholas A, Miller KK, et al. Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab. 2020;105(3):dgz187.
Öberg K, Lamberts SWJ. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: Past, present and future. Endocr Relat Cancer. 2016;23(12):R551–66.
Chin SO, Ku CR, Kim BJ, Kim SW, Park KH, Song KH, et al. Medical treatment with somatostatin analogues in acromegaly: Position statement. Endocrinol Metab. 2019;34(1):53–9.
Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, et al. The Mexican acromegaly registry: Clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997–4004.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2015;18(3):385–94.
Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398–404.
Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67(2):282–9.
Kyriakakis N, Seejore K, Hanafy A, Murray RD. Management of persistent acromegaly following primary therapy: The current landscape in the UK. Endocrinol Diabetes Metab. 2020;3(3):1–9.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: Crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord [Internet]. 2016;16(1):1–10. Available from: http://dx.doi.org/10.1186/s12902-016-0096-8
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Revista Endocrino